Description: Is 2024 the year you need to implement U.S. GAAP Long-Duration Targeted Improvements for individual health insurance products? In this session, we will discuss implementation and the importance of working with accountants and IT to ensure a successful implementation. Some requirements will be a surprise to health actuaries.

Description: Medicare Advantage plans have been in the market for two decades. In this session, we survey the landscape changes from 2006 up to now, which include but not limited to the changes of enrollment, plan types, big players' market share, policies, and how players as well as beneficiaries react to the changes. This session intends to provide general MA knowledge and history to the audience with or without Medicare Advantage background.

Description: Sarah Rockhill, MPH, Geospatial Epidemiologist at CDC will discuss the latest in the Public Health 3.0 model in which leaders serve as Chief Health Strategists, partnering across multiple sectors and leveraging data and resources to address social, environmental, and economic conditions that affect health and health equity.

Description: Value-based care (VBC) arrangements have grown exponentially in recent years with an expectation that this shift will only continue across the health care industry. CMS has set the goal of having 100% of traditional Medicare and the vast majority of Medicaid beneficiaries in accountable care relationships by 2030.

Description: The presenters will discuss market impacts of Affordable Care Act (ACA) risk adjustment results with a focus on recently released 2024 results. Their discussion will include the challenges of a single risk adjustment model and the growing state variations that impact risk dynamics.

Description: It happens every year: hurricanes, wildfires, and floods destroy property, interrupt routine care, and exacerbate chronic conditions. Clearly, general insurance and health actuaries need to reflect these conditions in their pricing projections even though there are lots of unanswered questions about the frequency, intensity, and location of significant events. In this session, the presenters will discuss how to reflect the impact of climate change in the day-to-day work of health and general insurance actuaries. After this session, attendees will be able to: - Describe the impact of climate change on property damage and healthcare - Identify relevant data sources and methods needed to reflect the impact of climate change for use in the day-to-day work of health and general insurance actuaries - Discuss the risk associated with climate change

Description: Many states have recently introduced mandatory paid family and medical leave (PFML) programs, which require employers to provide PFML benefits to their employees. This session explores recent trends in PFML programs, including plan design, pricing, employee perception, employer challenges, and current activity in various states.

Description: Enjoy an in-depth walkthrough of the facets of the lab testing world in this webcast. The agenda will include a discussion on genetic testing, which focuses on its general background, current trends and tests in the pipeline, as well as a focus on the approaches to achieve savings in lab testing. Finally, expect to check out sample actuarial analyses that will be used to identify areas of focus in lab management. Join us and take a deeper look into lab work in the actuarial health industry.

Description: Actuaries historically modeled new launches in pharmaceuticals by anticipating the expected change to the market basket. This became more complicated with the recent launches of gene and cell therapies as they address rare diseases. Rare conditions have low total member volume to study and some do not currently have a diagnosis code to identify them within claims data. Addressing this modeling challenge has been growing more important in the recent years with the number of therapies launching. What has the health care industry, and more specifically health care, done to enhance modeling and how should this be altered for the future? Additionally, historic modeling has sometimes incorporated a level of direct medical treatment cost offsets where studies have shown lower treatment costs are achievable. Can gene and cell financial modeling include cost offsets as well? And if so, what are suggested precautions or limitations to this effort?

Description: Discover a comparison of U.S. and international mandated leave programs which mandate employers to provide a minimum level of benefits to employees for qualifying leaves of absence, such as parental leave or medical leave.